Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(14%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
2
29%
Ph phase_3
4
57%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 34 (57.1%)

Trials by Status

completed686%
recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_2

Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

NCT07035561
recruitingphase_3

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

NCT06714838
completedphase_1

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

NCT01292603
completedphase_3

Rituximab in Auto-Immune Hemolytic Anemia

NCT01181154
completedphase_2

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

NCT00426543
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07035561Phase 2

Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

Completed
NCT06714838Phase 3

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Recruiting
NCT01292603Phase 1

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Completed
NCT01181154Phase 3

Rituximab in Auto-Immune Hemolytic Anemia

Completed
NCT00426543Phase 2

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Completed
NCT02079532Phase 3

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Completed
NCT00344149Phase 3

Rituximab as Second Line Treatment for ITP

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7